SEC investigating Illumina over acquisition of cancer test developer Grail
Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.
Source link
Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/7HQ2JI4QHVL3JLM3KLYIX6Z3HU.jpg "Germany could make COVID test or vaccine mandatory for public transport")